Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic
  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

SCIEX and Bioinformatics Solutions Inc. Further Collaboration for Proteomic Advancement

SCIEX, a global leader in life science analytical technologies, and Bioinformatics Solutions Inc. (BSI), provider of next-generation, deep learning proteomics and AI-driven biotechnology solutions, advance their collaboration with the co-development of PEAKS 12.5. This new software launch is fully compatible with the ZenoTOF 7600+ system, offering exclusive commercial support of ZT Scan DIA for proteomics applications.

In this latest software platform release, the unique de novo assisted pipeline together with deep learning algorithms exploit the data acquired from the scanning Q1 quadrupole dimension by ZT Scan DIA. The software does this by utilizing a new scoring algorithm integrating DDA and DIA data analysis approaches to reflect the increase in sensitivity and accuracy of identification and quantitation results achieved by the ZenoTOF 7600+ system. The Q1 dimension gives the data the DDA-like quality by associating precursor information to the MS/MS scans, thus improving accuracy and increasing identification and quantitation rates.

In addition, the software displays the Q1 profile of each identified peptide in an interactive GUI so that results can be easily interpreted and validated. Visualization of the Q1 profile demonstrates the added ability to deconvolve co-eluting fragment ion signals originating from native and modified peptides.

“Proteomic scientists need to know what the data looks like and why it’s happening, especially as results are brought into the medical field. PEAKS 12.5 is the only software tool to allow researchers to visualize the Q1 dimension from the ZenoTOF 7600+ system, meaning you can see the quality, the peak shape, the curvature. This can improve accuracy and scoring, and also help visually differentiate isomers,” said Baozhen Shan, Chief Executive Officer & Chief Scientific Officer at BSI.

“We are excited to build upon the collaboration with BSI that we set out on earlier this year. Together, SCIEX and BSI aim to help the proteomics community gain confidence in their data and translate their results into meaningful, actionable biology. Through our collaborative efforts of exploiting the multidimensional data from the ZenoTOF 7600+ system, we hope to see advancements to the role of proteomics research within precision medicine,” said Jose Castro-Perez, Vice President, Product Management.

To learn more about PEAKS Studio, see https://www.bioinfor.com/peaks-studio/.

This announcement marks the expansion of the relationship between SCIEX and BSI, as SCIEX becomes an official commercial reseller of the PEAKS Studio platform.

About SCIEX

SCIEX empowers our customers to solve the most impactful analytical challenges in quantitation and characterization. With groundbreaking innovation and outstanding reliability and support, SCIEX has been at the forefront of the field for over 50 years. ​

Since the launch of the first-ever commercially successful triple quadrupole in 1981, we continue to develop technologies and solutions that influence life-changing research and outcomes. That’s why thousands of life science experts around the world choose SCIEX to get the answers they can trust. ​Advances in human wellness depend on the power of precise science.​

For more information, visit sciex.com. ​

Connect with us on LinkedIn, Facebook, X (Twitter) and Instagram.​

SCIEX is proud to be part of Danaher. ​

Danaher’s science and technology leadership puts SCIEX solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher’s other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks).

© 2024 DH Tech. Dev. Pte. Ltd. MKT-33273-A.

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.